Barbui / Tefferi Myeloproliferative Neoplasms
2012
ISBN: 978-3-642-24989-1
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark
Critical Concepts and Management
E-Book, Englisch, 240 Seiten, eBook
Reihe: Hematologic Malignancies
ISBN: 978-3-642-24989-1
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark
This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Weitere Infos & Material
Biology:
Update
Do we need biology studies for patient management?
Gerneral Issues in the Management of MPNs:
Critical Issues about the Diagnosis of MPNs
Patient's Information and Examinations Needed before Planning Therapy
Specific Issues of Treatment in PV and ET:
Risk classification
Goal of Therapy
First-line Therapy and Monitoring the Response in the Individual Patient
Primary and Secondary Antithrombotic Prophylaxis
When to change Therapy: Second Line Options
The Evolution in Myelofibrosis and Leukemia
Treatment of PMF:
Current Clinical Needs
Risk Stratification
Goal of Therapy: Palliation and Curative
Research Issues and Perspectives:
New drugs
Ongoing Clinical Trials
How to Design Clinical Studies in Rare Diseases
